The impact of the follicular lymphoma (FL) histologic grade on outcomes after high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) is unknown. We evaluated 219 consecutive patients with grades 1-3 FL who underwent HDT and ASCT at our center. Overall survival (OS), progression-free survival (PFS), relapse and non-relapse mortality (NRM) was estimated for each grade after controlling for other predictive factors. The number of patients with grades 1, 2 and 3 FL was 106 (48%), 75 (34%) and 38 (17%), respectively. Five-year outcome estimates for the entire cohort included 60% OS, 39% PFS and 46% relapse (median follow-up ¼ 7.8 years). PFS and relapse were nearly identical among patients with grade 3 FL versus grades 1-2 FL after adjusting for other contributing factors (hazard ratio (HR) ¼ 0.90, P ¼ 0.68; HR ¼ 1.07, P ¼ 0.80, respectively). The hazard for mortality (HR ¼ 0.70, P ¼ 0.23) and NRM (HR ¼ 0.33, P ¼ 0.07) was non-significantly lower among patients with grade 3 FL compared to patients with grades 1-2 disease. Factors associated with inferior PFS included elevated lactate dehydrogenase (HR ¼ 1.52, P ¼ 0.03), chemoresistance (HR ¼ 1.82, P ¼ 0.02), X2 prior therapies (HR ¼ 1.8, P ¼ 0.03) and prior radiation (HR ¼ 1.99, P ¼ 0.003). These data suggest that the histologic grade of FL does not impact PFS or relapse following HDT and ASCT.
Introduction
Follicular lymphoma (FL) is the second most common non-Hodgkin's lymphoma and the most common indolent lymphoma, representing 420% of the approximately 56 000 new non-Hodgkin's lymphoma diagnoses made in the United States each year. [1] [2] [3] The World Health Organization considers FL to be a single entity that is stratified into three histologic grades based on the number of centroblasts per high-power field. 4 In contrast, the Working Formulation and the Kiel Classification consider follicular large cell/FL grade 3 to be a distinct biologically aggressive histopathologic disease. 5, 6 Similarly, controversy currently exists as to how histologic grade actually affects clinical outcomes for FL with some data suggesting that follicular large cell lymphoma behaves as other aggressive non-Hodgkin's lymphoma with a subset achieving cure following intensive therapy and other studies implying that FL grade 3 parallels the behavior of the grade 1-2 counterparts with a continuous risk of relapse and no plateau in the progression-free survival (PFS) curve. [7] [8] [9] [10] [11] [12] [13] Recent data suggest that high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) may benefit selected patients with FL. [14] [15] [16] [17] However, these studies either did not assess patients with all three FL subtypes or did not formally evaluate the potential impact of grade on outcome. Furthermore, these investigations demonstrated a continuous relapse rate over time, in contrast to the observations in aggressive non-Hodgkin's lymphoma, where a plateau in PFS has been observed. [18] [19] [20] Thus, limited data exist assessing the impact of histologic grade on outcomes following HDT and ASCT for FL. In this study, we addressed this issue by evaluating overall survival (OS), PFS, non-relapse mortality (NRM) and relapse for each histologic grade of FL after adjusting for other factors known or suspected to be associated with outcome among patients with FL. 
Patients and methods

Patients
Data collection and definitions
Clinical and research records were reviewed and baseline characteristics and follow-up data were recorded for each patient. The World Heath Organization classification schema was utilized to categorize FL grades. 4 In general, computerized tomographic re-staging was requested at 3, 6 and 12 months after transplantation and annually thereafter. Bone marrow evaluations were requested annually after transplantation. Disease progression was defined as any documented signs of relapse based on an increase in size of previous sites of disease, the development of new sites of disease or in the case of CR, a recurrence of disease. 21 Death due to any cause was classified as a failure for the end point of OS, and death without disease progression was classified as a failure for NRM. Death or disease progression was classified as a failure for the end point of PFS. Chemosensitive disease was defined as achieving a complete or partial response (X50% reduction) from the regimen immediately prior to transplant. Hazard ratios (HR) for OS, PFS, NRM and relapse reflect risks of death, death or relapse, non-relapse death and relapse, respectively. Histology at transplant was defined as the most recent histologic grade identified prior to transplantation.
Statistical analysis
Probability estimates for OS and PFS were obtained using the method of Kaplan and Meier. 22 Probabilities of relapse and NRM were summarized using cumulative incidence estimates. Death without relapse was regarded as a competing risk for relapse and relapse as a competing risk for NRM. Cox regression models were used to assess the association of histologic grade with the end points of OS, PFS, NRM and relapse after adjusting for other factors known or suspected to be associated with outcome. These other factors were measured prior to transplant and included age, stage, date of transplant, lactate dehydrogenase (LDH), remission status, chemosensitivity, bulk, conditioning regimen, number of prior chemotherapy regimens and prior radiation therapy (RT). A model among these non-grade factors was fit for each end point, and histologic grade was then added to each model to estimate the impact of grade on outcome, above and beyond what the non-grade factors contributed to outcome. Age was modeled as a continuous linear variable and the HR was presented as an increase in the risk of death associated with an age increase of 20 years. Bulk and prior number of chemotherapy regimens were modeled as continuous linear variables with the HRs representing increases in the risks of death associated with each increase in bulk category (o5, 5-10 and 410 cm) or the number of chemotherapy regimens received.
Results
Baseline characteristics
Two hundred and nineteen patients (134 men, 85 women) with FL were treated with HDT and ASCT. The baseline characteristics for these patients are summarized in Table 1 . One hundred and six (48%) patients had grade 1 FL, 75 (34%) patients had grade 2 FL and 38 (17%) patients had grade 3 FL. The median age at transplant was 48 (range: 24-66). One patient had stage I disease, 13 (6%) patients had stage II disease, 62 (28%) patients had stage III disease and 143 (65%) patients had stage IV disease. Fifty-nine (27%) patients had an abnormal LDH level. One hundred and fifty (68%) patients had chemosensitive disease, 32 (15%) patients had chemoresistant disease, 34 (16%) patients underwent HDT and ASCT without prior treatment for relapse and three (1%) had an unknown response to salvage chemotherapy. Forty of the chemosensitive patients were taken to transplant while in a CR. The median number of prior chemotherapy regimens was 3 One hundred and four (47%) grafts were purged. Marrow grafts were purged with a combination of anti-B-cell antibodies (for example, anti-CD9, -CD10, -CD19 and -CD20) and complement before cryopreservation, as described previously and peripheral blood stem cell grafts were purged with CD34 immunoadsorption (Isolex, Baxter Inc., Deerfield, IL, USA).
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Overall survival, progression-free survival and relapse Of the 219 patients, 115 (53%) are alive and 79 (36%) are alive and progression-free with a median follow-up of 7.8 years among the survivors. Sixty-six deaths occurred following relapse and 36 patients died without prior relapse. Causes of NRM included infection (n ¼ 13), pneumonitis (n ¼ 7), solid tumor (n ¼ 5), myelodysplastic syndrome/AML (n ¼ 2), cardiac arrest (n ¼ 1), hepatic toxicity (n ¼ 1) and unknown (n ¼ 7). The 5-year estimates of OS, PFS and relapse for the entire cohort were 60%, 39% and 46%, respectively ( Figure 1) . Prior anthracycline or prior rituximab had no impact on any of these end points (data not shown).
Impact of grade on overall survival
The 5-year OS estimates were 57% for patients with grade 1 FL, 60% for patients with grade 2 FL and 65% for patients with grade 3 FL (Figure 2 
Impact of grade on progression-free survival
The 5-year PFS estimates were 35% for patients with grade 1 FL, 44% for patients with grade 2 FL and 45% for patients with grade 3 FL (Figure 3 ). The hazard for death or progression was similar for all three FL grades after adjusting for the other factors significantly associated with Years after transplant Probability of survival 12 15 Figure 2
The effect of histologic grade on overall survival for 219 follicular lymphoma patients treated with high-dose therapy and autologous stem cell transplantation. PFS (number of prior regimens, presence of elevated LDH, treatment with prior radiation therapy and chemosensitivity) (Table 3) . When the adjusted hazard of death or relapse for grades 1-2 FL together was compared with grade 3, again, there was no suggestion of a difference in PFS (HR ¼ 0.90, 95% CI 0.56-1.46, P ¼ 0.68).
Impact of grade on relapse
The 5-year estimated probabilities of relapse were 49% for patients with grade 1 FL, 41% for patients with grade 2 FL and 47% for patients with grade 3 FL (Figure 4 ). There was little suggestion of a difference in relapse between grade 2 and grade 1 patients (HR ¼ 0.93, 95% CI 0.60-1.46, P ¼ 0.76) or between grade 3 and grade 1 patients (HR ¼ 1.04, 95% CI 0.60-1.80, P ¼ 0.88) after adjusting for the other contributing factors of number of prior regimens, treatment with prior radiation therapy and chemosensitivity (Table 4 ). The adjusted hazard of relapse among patients with grade 3 FL was also similar when compared to all patients with grades 1-2 FL combined (HR ¼ 1.07, 95% CI 0.64-1.81, P ¼ 0.80).
Impact of grade on non-relapse mortality
The 5-year estimated probabilities of NRM were 16% for patients with grade 1 FL, 15% for patients with grade 2 FL and 8% for patients with grade 3 FL ( Figure 5) . In an adjusted model controlling for the significant factor of age at transplant, the hazard of NRM among patients with grade 2 FL was similar to that among patients with grade 1 FL (HR ¼ 0.79, 95% CI 0.40-1.54, P ¼ 0.48) ( Table 5 ). In contrast, the adjusted hazard of non-relapse death among patients with grade 3 FL was significantly lower than that for grade 1 FL (HR ¼ 0.30, 95% CI 0.09-1.02, P ¼ 0.05).
The lower adjusted HR of non-relapse death for grade 3 Years after transplant Probability of PFS 12 15 Figure 3 The effect of histologic grade on progression-free survival for 219 follicular lymphoma patients treated with high-dose therapy and autologous stem cell transplantation. Table 3 Multivariable regression model for progression-free survival (relapse or mortality, 140 events)
Factor
Hazard ratio 95% CI P-value Probability of relapse Years after transplant 12 15 Figure 4 The effect of histologic grade on relapse for 219 follicular lymphoma patients treated with high-dose therapy and autologous stem cell transplantation. 
Discussion
In this study, we evaluated the impact of histologic grade on outcomes following HDT and ASCT for FL. Our data suggest that histologic grade is not correlated with PFS, or relapse in these patients, even after adjusting for other factors that impacted these end points. In contrast, patients with grade 3 FL experienced a 3-fold lower rate of NRM than patients with grade 1-2 disease that bordered statistical significance (HR ¼ 0.33, P ¼ 0.07, Figure 5 ) likely providing the major contribution to the non-significant 30% reduction in overall mortality observed in the grade 3 cohort (HR ¼ 0.70, 95% CI 0.39-1.26, P ¼ 0.23, Figure 2 ). Our findings address the controversy surrounding the biology of grade 3 FL as to whether clinically it behaves more akin to diffuse large B-cell lymphoma or more like FL grades 1 and 2. 9, 10, 24, 25 The results from this study imply that transplant for FL has similar outcomes for end points that may reflect the 'curability' of the disease (for example, relapse, PFS) regardless of grade or the fraction of large cells/centroblasts within the follicular architecture since the PFS and relapse curves were closely matched. Such conclusions would support the World Health Organization grouping of all FL as a single biological entity. 4 The major outcome disparity observed was the reduced NRM seen in the grade 3 patients when compared to those with grade 1-2 disease, which is more likely a reflection of patient factors rather than histologic grade.
Despite the fact that no statistically significant differences in OS, PFS, and relapse were observed between the three histologic grades in this study, the overall conclusions should be tempered by the inevitable retrospective study design and potential limited statistical power due the small number of patients with grade 3 disease. Future analyses should ideally focus on cohorts of prospectively assessed FL patients following uniform treatment and supportive care. Other investigators have also attempted to address the question of whether grade 3 FL is a distinct biological entity by further subdividing FL grade 3 into grades 3a and 3b, implying that the former shares characteristics of FL grades 1 and 2 and the latter closely mimics diffuse large B-cell lymphoma. 26 Yet others have observed that the presence of 450% diffuse component portends an inferior outcome after primary therapy for FL grade 3, although such patients were by definition excluded from our analysis. 27 Evaluating the proliferative rate as measured by Ki-67 staining has also been shown to be predictive of more aggressive clinical behavior. 28 One could anticipate that in the future, molecular signatures of individual tumors or the infiltrating immune cells may be the most precise pathologic predictors of outcomes for FL. 29, 30 Unfortunately, the retrospective design of this study did not allow us to evaluate these factors uniformly.
Nevertheless, based on our analysis, it appears that histologic grade as defined by the World Health Organization classification system does not have a statistically significant impact on the primary outcomes that may reflect the biology of FL in patients undergoing HDT and ASCT, and any suggestion of differences in OS and PFS in this series are likely explained by a reduced NRM in grade 3 patients. We, therefore, propose that FL histologic grade should not be used as a primary basis for counseling patients on predicted outcomes or comparing results between studies of HDT and ASCT for FL, whereas, other factors such as age, chemosensitivity, LDH and prior therapy may prove more clinically useful. Years after transplant Probability of NRM 12 15 Figure 5
The effect of histologic grade on non-relapse mortality for 219 follicular lymphoma patients treated with high-dose therapy and autologous stem cell transplantation. Table 5 Multivariable regression model for non-relapse mortality (36 events)
Factor
Hazard ratio 95% CI P-value 
